CA-THEOREMONE
25.1.2022 00:39:08 CET | Business Wire | Press release
Theorem, LLC, innovation and engineering partner to the Global 1000, today announced that it has rebranded to TheoremOne® following an acquisition of Formula Partners , and launch of its near-shore, pureplay software engineering service, Lemma . The new name positions TheoremOne as the foundation of a family of brands designed to help enterprises build better, more innovative business platforms at scale.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220124005847/en/
“Our new name positions TheoremOne as the foundation of a family of brands, all inspired by our hypothesis driven model for innovation. Each brand is designed to address the specific needs of our clients at different moments in the lifecycle of enterprise innovation,” said Brady Brim-DeForest, CEO of TheoremOne.
Its newest acquisition, Formula Partners, helps companies create new models for organizational design, continuous improvement, and visionary leadership. Formula Partner’s approach revolves around a modular innovation process called the New Enterprise™, a proprietary model for modern consulting at the nexus of technology and organizational transformation. Formula Partners will become a new independent line of business and will operate under the “Formula Partners” brand.
“We are approaching management consulting from 14 years of implementing technology solutions — giving us a deep understanding of the true benefits (and costs) of making strategic recommendations. We’ve built trust with IT and business leaders through hands-on work, and we’re excited to build even broader strategic relationships through Formula Partners,” said Will Jessup, Head of Services Delivery at TheoremOne.
TheoremOne has also launched a new engineering service called Lemma. Lemma offers pureplay software engineering teams staffed exclusively by nearshore engineering talent. Lemma shares a common engineering DNA with TheoremOne but is designed to deliver engineering capacity as a modular service offering that can be deployed to scale existing teams and initiatives for enterprise and growth stage clients.
“Lemma fills a gap in our offerings that the market has illuminated over the last few years,” said Alex Finnemore, TheoremOne’s Head of Revenue. “It’s a compelling option for clients that have already determined the right way to solve a business problem and need a dedicated technology partner, but want to provide their own product, design, and leadership talent.”
Lemma and Formula Partners will join existing divisions Proof (staff augmentation) and Halmos Ventures (innovation incubation) in rounding out TheoremOne’s end-to-end services stack.
As part of the name change, TheoremOne has released a new company logo and launched a new website at www.theoremone.co .
About TheoremOne®
TheoremOne is an innovation and engineering firm that builds custom software for companies making bold bets to stay ahead. Through research, lean design, and agile delivery, TheoremOne makes great user experiences accessible to the enterprise. Founded in 2007, TheoremOne’s global cross-functional product development teams drive technology, process, and cultural transformation. To learn more about how TheoremOne enables ambitious leaders to build better software visit www.theoremone.co or follow @TheoremOne
About Formula Partners
Formula Partners is a different kind of management consulting firm — it targets the intersection of technology and organizational transformation, unlocking models for continuous improvement, and enabling visionary leadership within the enterprise. Founded in 2015, Formula Partners is based in Los Angeles. Read more at: www.formula.partners .
About Lemma
Lemma offers pureplay software engineering teams designed to deliver high-quality results at-scale. Clients come to Lemma when they need an injection of fully-managed and modular engineering talent. Learn more about Lemma at: www.thinklemma.com
View source version on businesswire.com: https://www.businesswire.com/news/home/20220124005847/en/
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Codethink Opens Early Access to IEC 61508 Mapping for the Eclipse Trustable Software Framework11.3.2026 08:07:00 CET | Press release
Preview release invites industry collaboration on open source approach to functional safety assessment EMBEDDED WORLD--Codethink today opened early access to its mapping between the Eclipse Trustable Software Framework (TSF) and IEC 61508, the international standard governing the functional safety of electrical and electronic systems. The mapping establishes a transparent relationship between the engineering principles of the Trustable Software Framework and the objectives defined in IEC 61508. By making this work available as an early preview, Codethink is inviting organisations interested in applying open source approaches to functional safety to review and begin working with the mapping while the work continues to mature. IEC 61508 forms the foundation of many domain-specific safety standards, including ISO 26262 for automotive systems. The early access reflects Codethink’s long-standing commitment to open development of software engineering methods. “This preview release reflects o
Galderma Buys Back Shares Worth CHF 232 Million in the Context of Accelerated Bookbuild Offering11.3.2026 07:00:00 CET | Press release
Ad hoc announcement pursuant to Art. 53 LR Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that it has agreed to repurchase 1.6 million shares at a price of CHF 143.75 per share for a total consideration of CHF 232 million in the context of the accelerated bookbuild offering (“ABO”) of Galderma shares by Sunshine SwissCo GmbH (“EQT”), Abu Dhabi Investment Authority (Private Equities Department) and Auba Investment Pte. Ltd. (all together the “Selling Shareholders”) launched yesterday evening. The repurchase was made at the same price per share determined by the bookbuilding offering. As a result of yesterday evening’s ABO, the Selling Shareholders have fully divested their remaining stake in Galderma. The repurchase, which is expected to settle on March 13 is being financed by Galderma’s existing liquidity on hand and will not affect the company’s ability to deliver on its strategic and financing priorities. The shares will be held in treasury for futur
Thales Launches SkyDefender: The Integral Air and Missile Defence Dome With Artificial Intelligence11.3.2026 07:00:00 CET | Press release
SkyDefender is a multi-layer, multi-domain Integrated Air and Missile Defence system providing full protection against all types of air threats, on land, at sea and in space. SkyDefender integrates a network of advanced sensors and effectors with a versatile command and control (C2) system. With its open and modular architecture, it is fully compatible with existing air defence systems. Combining Thales’ expertise in cybersecurity and advanced artificial intelligence through cortAIx, Thales AI accelerator, SkyDefender enables operational superiority and proactive defence against cyberattacks and evolving threats. Thales is capable of delivering this critical protection globally from today. As air and missile threats are evolving faster than ever, from slow-moving drones to hypersonic missiles, attacks are becoming increasingly complex, saturating and unpredictable. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260310398606/
Curatis and Neupharma Announce Exclusive Licensing Agreement to Develop and Market Corticorelin (C-PTBE-01) for the Treatment of Peritumoral Brain Edema in Japan11.3.2026 07:00:00 CET | Press release
Japan is one of the world's most important pharmaceutical markets after the US and Europe. Neupharma’s team has extensive experience in developing and successfully commercialising orphan drugs as well as speciality care medicines in Japan, including a blockbuster drug. The agreement with Neupharma includes upfront and milestone payments of up to CHF 83.5 million as well as royalties of up to 20% on sales. The population of available patients eligible for corticorelin treatment associated with peritumoral brain edema is estimated at 60,000 in Japan and 500,000 worldwide. Global market potential is forecasted to exceed USD 1 billion annually. Curatis Holding AG (SIX: CURN) and Neupharma Co., Ltd. (“Neupharma”), a Japanese pharmaceutical company specializing in oncology, immunology, pulmonology and cardiology disorders, today announce an exclusive license and development agreement for corticorelin (C-PTBE-01) in Japan. Under the terms of the agreement, Neupharma will receive exclusive rig
Galderma Completes Successful Placement of EUR 500 Million Eurobond11.3.2026 06:55:00 CET | Press release
Galderma Group AG (SWX:GALD): NOT FOR DISTRIBUTION IN THE UNITED STATES OR IN ANY OTHER JURISDICTION IN WHICH SUCH DISTRIBUTION WOULD BE RESTRICTED BY APPLICABLE LAW OR REGULATION. Galderma Group AG (SIX:GALD), the pure-play dermatology category leader, today announced the successful placement of a single-tranche EUR 500 million Eurobond. The bond has a 5-year maturity and carries a fixed-rate annual coupon of 3.375%. The Eurobond was placed on March 10, 2026, with settlement expected on March 17, 2026, and will be listed on the SIX Swiss Exchange. Citigroup, ING, J.P. Morgan and RBC Capital Markets jointly led the transaction. Net proceeds from the transaction will be used to fully repay Galderma’s existing bank term loan issued in connection with the company’s initial public offering in March 2024. The transaction represents the final step in Galderma’s refinancing process, having obtained two investment grade credit ratings. Galderma is currently rated ‘BBB’ (stable outlook) by Fitc
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom